US Renal Data system. 2004 USRDS 2004 Annual data report Bethesda, MD National Institute of Health, National Institute of Diabetes and Digestive and Kidney Disease.
Foley RN, Parfrey PS, Sarnak MJ. 1998 Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32 (5Suppl 3
Massry SG, Smogorzewski M. 1994 Mechanism to which parathyroid hormone mediates its deleterious effects on organ function in uremia. Semin Nephrol 14:219–231.PubMed
Silver J, Kilav R, Naveh-Many T. 2002 Mechanisms of secondary hyperparathyroidism. Am J Physiol Renal Physiol 283:F367–376.PubMed
Block JA, Hulbert-Shearon TE, Levin NW, Port FK. 1998 Association of serum phosphorus and calcium X phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31:607–617.PubMed
Llach F, Yudd M. 1998 The importance of hyperphosphatemia in the severity of hyperparathyroidism and its treatment in patients with chronic renal failure. Nephrol Dial Transplant 13(Suppl 13
Malluche HH, Monier-Faugere MC. 1999 Understanding and managing hyperphosphatemia in patients with chronic renal failure. Clin Nephrol 52:267–277.PubMed
Shigematsu T, Kazama JJ, Yamashita T et al. 2004 Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 44:250–256.PubMedCrossRef
Inaba M, Nakatsuka K, Nagasue K et al. 2004 FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int 65:1943–1946.PubMedCrossRef
Fukuda N, Tanaka H, Tominaga Y et al. 1993 Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 92:1436–1443.PubMed
Gogusev J, Duchambon P, Hory B et al. 1993 Depressed expression of calcium receptor in parathyroid gland Tissue of patients with hyperparathyroidism. Kidney Int 1993 Jan:51(1):328–336.CrossRef
Yano S, Sugimoto T, Tsukamoto T et al. 2000 Association of decreased calcium-sensing receptor expression with proliferation of parathyroid cells in secondary hyperparathyroidism. Kidney Int 58:1980–1986.PubMedCrossRef
Kifor O, Moore FD Jr, Wang P et al. 1996 Reduced immunostaining for the extracellular Ca2+sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab 81:1598–1606.PubMedCrossRef
Korkor AB. 1987 Reduced binding of [3H]1,25-dihydroxyvitamin D3 in the parathyroid glands of patients with renal failure. N Engl J Med 316:1573–1577.PubMedCrossRef
Dusso AS. 2003 Vitamin D receptor: mechanisms for vitamin D resistance in renal failure. Kidney Int (Suppl) Jun;(85):S6–9. Review.
Silver J. 2002 Pathogenesis of parathyroid dysfunction in end-stage renal disease Adv Ren Replace Ther 9: 159–167.PubMedCrossRef
Sherrard DJ, Hercz G, Pei Y et al. 1993 The spectrum of bone disease in chronic renal failure-an evolving disorder. Kidney Int 43:436–442.PubMedCrossRef
Malluche HH, Monier-Faugere MC. 1990 Renal bone disease 1990; an unmet challenge for the nephrologist. Kidney Int 38:193–211.PubMedCrossRef
Hruska KA, Teitelbaum SL. 1995 Renal osteodystrophy. N Engl J Med 333:166–174.PubMedCrossRef
Brown AJ, Zhong M, Finch J, Ritter C, Slatopolsky E. 1995 The roles of calcium and 1,25-dihydroxyvitamin D3 in the regulation of Vitamin D receptor expression by rat parathyroid glands. Endocrinology 136:1419–1425.PubMedCrossRef
Quarles LD. 2005 Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism in stage 5 chronic kidney disease. Kidney Int (Suppl) Jul;(96):S24–28. Review.
Dusso AS, Thadhani R, Slatopolsky E. 2004 Vitamin D receptor and analogs. Semin Nephrol 24:10–16.PubMedCrossRef
Mizobuchi M, Hatamura I, Ogata H et al. 2004 Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency. J Am Soc Nephrol 15:2579–2587.PubMedCrossRef
Goldenberg MM. 1999 Paricalcitol, a new agent for the management of secondary hyperparathyroidism in pa-tients undergoing chronic renal dialysis. Clin Ther 21:432–441.PubMedCrossRef
Brown AJ, Zhong M, Finch J, Ritter C, Slatopolsky E. 1995 The roles of calcium and 1,25-dihydroxyvitamin D3 in the regulation of vitamin D receptor expression by rat parathyroid glands. Endocrinology 136:1419–1425.PubMedCrossRef
Alfrey AC, LeGendre GR, Kaehny WD. 1976 The dialysis encephalopathy syndrome. Possible aluminum intoxication. N Engl J Med 294184–188.
Smith AJ, Faugere MC, Abreo K et al. 1986 Aluminum-related bone disease in mild and advanced renal failure: evidence for high prevalence and morbidity and studies on etiology and diagnosis. Am J Nephrol 6:275–283.PubMed
Faugere MC, Malluche HH. 1986 Stainable aluminum and not aluminum content reflects bone histology in dialysis patients. Kidney Int 30:717–722.PubMedCrossRef
Faugere MC, Malluche HH. 1996 Trends in renal osteodystrophy: a survey from 1983 to 1995 in a total of 2248 patients. Nephrol Dial Transplant 11:111–120.
Malluche HH, Faugere MC. 1988 Aluminum related bone diseases. Blood Purif 6:1–15.PubMed
Goodman WG. 1985 Bone disease and aluminum: pathogenic considerations. Am J Kidney Dis 6:330–335.PubMed
Sedman AB, Alfrey AC, Miller NL, Goodman WG. 1987 Tissue and cellular basis for impaired bone formation in aluminum related osteomalacia in pig. J Clin Invest 79:86–92.PubMed
Quarles LD, Dennis VW, Gitelman GJ, Harrelson JM, Drezner MK. 1985 Aluminum deposition at the osteoid-bone interface. An epiphenomenon of the osteomalacic state in vitamin-D deficient dogs. J Clin Invest 75:1441–1447.PubMed
Goodman WG, Leite Duarte ME. 1991 Aluminum: effects on bone and role in the pathogenesis of renal osteodystrophy. Miner Electrolytes Metab 17:221–232.
Goodman WG, O’Connor J. 1991 Aluminum alters calcium influx and efflux from bone in vitro. Kidney Int 39:602–607.PubMedCrossRef
Malluche HH, Faugere MC, Smith AJ Jr, Friedler RM. 1986 Aluminum intoxication of bone in renal failure—fact or fiction? Kidney Int (Suppl) 18:S70–73.
D’Haese PC, Couttenye MM, De Broe ME. 1996 Diagnosis and treatment of aluminum bone disease. Nephrol Dial Transplant 1:74–79.
Diaz-Corte C, Fernandez-Martin LJ, Barreto S et al. 2001 Effect of aluminum load on parathyroid hormone synthesis. Nephrol Dial Transplant 16:742–745.PubMedCrossRef
Nordal KP. 1996 Calcium carbonate versus aluminum hydroxide as phosphate binder in hemodialysis patients. A randomized prospective study. Kidney Int 49:926.
Locatelli F, Cannata-Andia JB, Drueke TB et al. 2002 Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia. Nephrol Dial Transplant 17:723–731.PubMedCrossRef
Martinez I, Saracho R, Montenegro J, Llach F. 1997 The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure. Am J Kidney Dis 29:496–502.PubMed
Combe C, Aparicio M. 1994 Phosphorus and protein restriction and parathyroid function in chronic renal failure. Kidney Int 46:1381–1386.PubMedCrossRef
Hou SH, Zhao J, Ellman CF et al. 1991 Calcium and phosphorus fluxes during hemodialysis with low calcium dialysate. Am J Kidney Dis 18:217–224.PubMed
Achinger SG, Ayus JC. 2005 The role of daily dialysis in the control of hyperphosphatemia. Kidney Int (Suppl) Jun;(95):S28–32.
Emmett M, Sirmon MD, Kirkpatrick WG et al. 1991 Calcium acetate control of serum phosphorus in hemodialysis patients. Am J Kidney Dis 17:544–50.PubMed
Mai ML, Emmett M, Sheikh MS et al. 1989 Calcium acetate, an effective phosphorus binder in patients with renal failure. Kidney Int 36:690–695.PubMedCrossRef
Pflanz S, Henderson IS, McElduff N, Jones MC. 1994 Calcium acetate versus calcium carbonate as phosphatebinding agents in chronic haemodialysis. Nephrol Dial Transplant 9:1121–1124.PubMed
Schaefer K, Scheer J, Asmus G et al. 1991 The treatment of uraemic hyperphosphataemia with calcium acetate and calcium carbonate: a comparative study. Nephrol Dial Transplant 6:170–175.PubMed
National Kidney Foundation. 2003 K/DOQI clinical practice guidelines for bone metabolism and disease in chronic hemodialysis patients. J Am Kidney Dis 42(Suppl 3): S1–202.
Salusky IB, Foley J, Nelson P, Goodman WG. 1991 Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease. N Engl J Med 324:527–531.PubMedCrossRef
Hsu CH. 1997 Are we mismanaging calcium and phosphate in renal failure? Am J Kidney Dis 29:641–649.PubMed
Salusky IB, Ramirez JA, Oppenheim WL et al. 1994 Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD. Kidney Int 45:253–258.PubMedCrossRef
Llach F, Fensenfeld AJ, Coleman MD, Pederson JA. Prevalence of various types of bone disease in dialysis patients. Nephrology, Proceedings of the ninth International Congress of Nephrology, vol II, edited by Robinson RR, New-York, Springer Verlag, 1984, 1375–1382.
Kurz P, Mauniere-Faugere MC, Bognar B et al. 1994 Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 46:855–861.PubMedCrossRef
London MG, Marty C, Marchais SJ et al. 2004 Arterial calcification and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 15:1943–1951.PubMedCrossRef
Guerin AP, London GM, Marchais SJ, Metivier F. 2000 Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 15:1014–1021.PubMedCrossRef
Fournier A, Moriniere P, Cohen-Solal ME et al. 1991 Adynamic bone disease in uremia: may it be idiopathic? Is it an actual disease? Nephron 58:1–12.PubMed
Frost HF. 1963 Measurement of human bone formation by means of tetracycline labeling. Can J Biochem Biophys 41:31–38.
Coco M, Rush H. 2000 Increase incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 36:1115–1121.PubMed
Mittalhenkle A, Gillen DL, Stehman-Breen CO. 2004 Increased risk of mortality associated with hip fracture in the dialysis population. Am J Kidney Dis 44:672–679.PubMedCrossRef
Wilkes BM, Reiner D, Kern M et al. 1998 Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenGel) in dialysis patients. Clin Nephrol 50:381–386.PubMed
Bleyer AJ, Burke SK, Dillon M et al. 1999 A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 33:694–701.PubMed
Hervas JG, Prados D, Cerezo S. 2003 Treatment of hyperphosphatemia with sevelamer hydrochloride in hemodialysis patients: a comparison with calcium acetate. Kidney Int Suppl Jun;(85):S69–72.
Qunibi WY, Hootkins RE, McDowell LL et al. 2004 Treatment of hyperphosphatemia in hemodialysis patients: The calcium acetate renagel evaluation (CARE study). Kidney Int 65:1914–1926.PubMedCrossRef
Chertow GM, Burke SK, Raggi P. 2002 Treat to goal working group: sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62:245–252.PubMedCrossRef
Behets GJ, Gritters M, Dams G, De Broe ME, D’Haese PC. 2005 Effects of efficient phosphate binding on bone in chronic renal failure rats. Ren Fail 27:475–84.PubMed
Drug Topic 2003 Redbook, Monvale, NJ, Thomson PDR, 2003.
Behets GJ, Verberckmoes SC, D’Haese PC, De Broe ME. 2004 Lanthanum carbonate: a new phosphate binder. Curr Opin Nephrol Hypertens 13:403–409. Review.PubMedCrossRef
Lacour B, Lucas A, Auchere D et al. 2005 Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int 2005 Mar;67(3):1062–1069.CrossRef
Slatopolsky E, Liapis H, Finch J. 2005 Progressive accumulation of lanthanum in the liver of normal and uremic rats. Kidney Int 68:2809–2813.PubMedCrossRef
Bervoets AR, Oste L, Behets GJ et al. 2006 Development and reversibility of impaired mineralization associated with lanthanum carbonate treatment in chronic renal failure rats. Bone Jan 10; (E pub ahead of print).
Damment SJ, Shen V. 2005 Assessment of effects of lanthanum carbonate with and without phosphate supplementation on bone mineralization in uremic rats. Clin Nephrol 63:127–137.PubMed
Hutchinson AJ. 1999 Calcitriol, lanthanum carbonate and other phosphate binders in the management of renal osteodystrophy. Perit Dial Int 19(Suppl 2):408–412.
Finn WF, Joy MS, Hladik G, Lanthanum Study Group. 2004 Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis. Clin Nephrol 62:193–201.PubMed
Joy MS, Finn WF, LAM-302 Study Group. 2003 Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis 42:96–107.PubMedCrossRef
D’Haese PC, Spasowski GB, Sikole A et al. 2003 A multicenter study on the effect of lanthanum carbonate (Forsenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int 63(Suppl 65
Hergesell O, Ritz E. 1999 Phosphate binders on iron bases: a new perspective. Kidney Int 56(Suppl 73
Holick MF. 2005 Vitamin D for health and in chronic kidney disease. Semin Dial 18:266–275.PubMedCrossRef
Zanello SB, Collins ED, Marinissen MJ, Norman AW, Boland RL. 1997 Vitamin D receptor expression in chicken muscle tissue and cultured myoblasts. Horm Metab Res 29:231–236.PubMedCrossRef
Tovar Sepulveda VA, Weigel NL, Falzon M. 2006 Prostate cancer cell type-specific involvement of the VDR and RXR in regulation of the human PTHrP gene via a negative VDRE. Steroids 71:102–115 (E pub 2005 Oct 21).CrossRef
Albrechtsson E, Jonsson T, Moller S et al. 2003 Vitamin D receptor is expressed in pancreatic cancer cells and a vitamin D3 analogue decreases cell number. Pancreatology 2003;3(1):41–46.PubMedCrossRef
Chang TJ, Lei HH, Yeh JI et al. 2000 Vitamin D receptor gene polymorphisms influence susceptibility to type1 diabetes mellitus in the Taiwanese population. Clin Endocrinol (Oxf) 52:575–80.CrossRef
McGrath JJ, Feron FP, Burne TH, Mackay-Sim A, Eyles DW. 2004 Vitamin D3-implications for brain development. J Steroid Biochem Mol Biol 89–90:557–560. Review.PubMedCrossRef
Nguyen TM, Pavlovitch J, Papiernik M et al. 1997 Changes in 1,25-(OH)2D3 synthesis and its receptor expression in spleen cell subpopulations of mice infected with LPBM5 retrovirus. Endocrinology 138:5505–5510.PubMedCrossRef
Christiansen C, Christensen MS, Melsen F, Rodbro P, DeLuca HF. 1981 Mineral metabolism in chronic renal failure with special reference to serum concentrations of 1.25(OH)2D and 24.25(OH)2D. Clin Nephrol 15:18–22.PubMed
Fratzl-Zelman N, Glantschnig H, Rumpler M et al. 2003 The expression of matrix metalloproteinase-13 and osteocalcin in mouse osteoblasts is related to osteoblastic differentiation and is modulated by 1,25-dihydroxyvitamin D3 and thyroid hormones. Cell Biol Int 27 459–468.PubMedCrossRef
Staal A, Geertsma-Kleinekoort WM, Van Den Bemd GJ et al. 1998 Regulation of osteocalcin production and bone resorption by 1,25-dihydroxyvitamin D3 in mouse long bones: interaction with the bone-derived growth factors TGF-beta and IGF-I. J Bone Miner Res 13:36–43.PubMedCrossRef
Gram J, Junker P, Nielsen HK, Bollerslev J. 1996 Dose-response effect of short-term calcitriol treatment on bone and mineral metabolism in normal males. Bone 18:539–544.PubMedCrossRef
Bro S, Olgaard K. 1997 Effects of excess PTH on non-classical target organs. Am J Kidney Dis 30:606–620.PubMed
Silver J, Russell J, Sherwood LM. 1985 Regulation by vitamin D metabolites of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells. Proc Natl Acad Sci U S A 82:4270–4273.PubMedCrossRef
Salusky IB, Goodman WG. 2001 Adynamic renal osteodystrophy: is there a problem? J Am Soc Nephrol 12:1978–1985. Review.PubMed
Salusky IB, Kuizon BD, Belin TR et al. 1998 Intermittent calcitriol therapy in secondary hyperparathyroidism: a comparison between oral and intraperitoneal administration. Kidney Int 54:907–914.PubMedCrossRef
Goodman WG, Ramirez JA, Belin TR. 1994 Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 46:1160–1166.PubMedCrossRef
Goodman WG, Salusky IB. 1991 Evolution of secondary hyperparathyroidism during oral calcitriol therapy in pediatric renal osteodystrophy. Contrib Nephrol 90:189–195.PubMed
Takahashi F, Finch JL, Denda M et al. 1997 A new analog of 1,25-(OH)2D3, 19-NOR-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content. Am J Kidney Dis 30:105-.PubMed
Slatopolsky E, Finch J, Ritter C et al. 1995 A new analog of calcitriol, 19-nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Am J Kidney Dis 26:852–860.PubMed
Staniforth ME, Cheng SC, Coyne DW. 2005 Once-weekly intravenous paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients. Clin Nephrol 63:454–460.PubMed
Coyne DW, Grieff M, Ahya SN et al. 2002 Differential effects of acute administration of 19-Nor-1,25-dihydroxyvitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients. Am J Kidney Dis 40:1283–1288.PubMedCrossRef
Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D. 2003 Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 63:1483–1490.PubMedCrossRef
Teng M, Wolf M, Lowrie E et al. 2003 Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349:446–456.PubMedCrossRef
Dobrez DG, Mathes A, Amdahl M et al. 2004 Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. Nephrol Dial Transplant 19:1174–1181.PubMedCrossRef
Torres PU. Clinical experience with cinacalcet HCl. 2004 Nephrol Dial Transplant 19(Suppl 5
Block GA, Martin KJ, de Francisco AL et al. 2004 Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350:1516–1525.PubMedCrossRef
Vadam M, Nagano N, Furuya Y et al. 2000 Calcimimetic NPS R-568 prevent parathyroid hyperplasia in rats with severe secondary hyperparathyroidism. Kidney Int 57:50–58.CrossRef
Vadam M, Furuya Y, Sakiyama J et al. 1997 The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via calcium receptor. J Clin Invest 100:2977–2983.CrossRef
Vadam M, Furuya Y, Sakiyama J et al. 1997 NPS R-568 halts or reverses osteoitis fibrosis in uremic rats. Kidney Int 53:448–453.
Goodman WG, Fravo GM, Goodkin DA et al. 2000 A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 58:436–445.PubMedCrossRef
Lindberg JS, Moe SM, Goodman WG et al. 2003 Calcimimetic AMG 073 reduces parathyroid hormone and calcium X phosphate in secondary hyperparathyroidism. Kidney Int 63:248–254.PubMedCrossRef
Drueke TB, Cunningham J, Goodman WG et al. 2001 Short term treatment of secondary hyperparathyroidism (SHPT) with calcimimetic agent AMG073. Am J Soc Nephrol 12:764A.
De Francisco ALM, Surany M, Cunningham J et al. 2003 Oral cinacalcet HCl (AMG073) for the treatment of hemodialysis patients with secondary hyperparathyroidism, results of an European/Australian phase 3 study. J Am Soc Nephrol 14:461A.
Brach GA, Martin KJ, De Francisco ALM et al. 2004 Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350:1520–1529.
Lindberg JS, Culleton B, Wong G et al. 2003 Phase 3 experience with cinacalcet HCl and hemodialysis and peritoneal dialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 14:36A.
Moe SM, Cunningham J, Bommer J et al. 2005 Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant 20:2186–2193.PubMedCrossRef
Yasunaga C, Nakamoto M, Matsuo K, et al. Effects of parathroidectomy on the immune system and nutritional condition in chronic dialysis patients with secondary hyperparathyroidism. Am J Surg 1999; 178: 332.PubMedCrossRef
Garcia-Clanton C, Palomar R, Moreno A, et al. Evolution of anemia of chronic renal failure after the treatment of hyperparathyroidism. Nephron 1996; 74: 444.
Hercz G, Pei Y, Greenwood C, et al. Aplastic osteodystrophy without aluminum: The role of “suppressed” parathyroid function. Kidney Int 1993; 44: 860.PubMedCrossRef
Gagne ER, Urena P, Silva SL, et al. Short and long-term efficacy of total parathyroidectomy with immediate ato-grafting compared with sub-total parathyroidectomy. in hemodialysis patients. J Am Soc Nephrol 1992; 3:1008.PubMed
Agus Z, Berkoben M, Quarles LD. Hungry bone syndrome following parathyroidectomy. UptoDate 2007.
Kitaoka M, Onoda N, Kitamura H, et al. Percutaneous calcitriol injection therapy (PCIT) for secondary hyperparathyroidism: multicentre trial. Nephrol Dial Transplant 2003; 18 Suppl 3: III38.
Evenepoel P, Claes K, Kuypers D, et al. Impact of parathyroidectomy on renal graft function, blood pressure and serum lipids in kidney transplant recipients: a single center study. Nephrol Dial Transplant 2005; 20:1714.PubMedCrossRef